HIV/AIDS

GHSC-PSM provides assistance that is targeted to support countries in meeting their unique procurement and supply chain challenges and, in some cases, to cut the cost of doing so. We work with suppliers of pharmaceuticals (antiretrovirals [ARVs] and essential medicines), male circumcision commodities, and laboratory instruments and commodities to reach this goal. The project collaborates with the Global Health Supply Chain-Rapid Test Kits (GHSC-RTK) project by providing country quantifications of demand for test kits. GHSC-PSM also works with Global Health Supply Chain-Quality Assurance (GHSC-QA) to ensure the quality of all HIV-related commodities.

Led by PEPFAR, UNAIDS, WHO, and others global stakeholders, many HIV/AIDS programs are transitioning to a new antiretroviral drug regimen, TLD (tenofovir, lamivudine, dolutegravir). GHSC-PSM is playing a vital role in supporting HIV/AIDS programs in managing their transition to TLD.

Our project teams work in 24 countries, providing a mix of technical assistance and/or commodity procurement support to strengthen local capacity in HIV supply chains. Building on a decade of work by USAID, PEPFAR, and implementing partners, our teams work with local partners to provide new approaches to strategic planning, logistics, data visibility and analytics, and capacity building.

Current country and regional presence includes: Angola, Botswana, Burundi, Cambodia, Cameroon, Caribbean, Central America, Ethiopia, Ghana, Guyana, Haiti, Indonesia, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Rwanda, South Sudan, Uganda, Vietnam, Zambia, and Zimbabwe.

Key commodities include:

• First-line adult antiretroviral medicines (ARVs)
• Second-line adult antiretroviral medicines (ARVs)
• First-line pediatric antiretroviral medicines (ARVs)
• All laboratory commodities
• Condoms
• Voluntary medical male circumcision
• Other related commodities

GHSC-PSM supports bold targets set by the U.S. government in 2015 for PEPFAR to support 12.9 million people with life-saving antiretroviral treatment and 13 million men with male circumcision by the end of 2017.

Specifically, our project advances PEPFAR’s work to support partner countries to rapidly adopt and implement World Health Organization (WHO) guidelines for “Test and Start” as well as more efficient service delivery models. These WHO guidelines are designed to prevent new HIV infections, save more lives, and accelerate progress toward the UNAIDS 90-90-90 goals for 2020:

• 95 percent of people with HIV diagnosed
• 95 percent of those diagnosed on antiretroviral treatment (ART)
• 95 percent of those on ART virally suppressed

GHSC-PSM contributes to each of the 95-95-95 targets through procurement and technical assistance. We collaborate closely with the Global Fund to Fight AIDS, Tuberculosis and Malaria and U.S. Centers for Disease Control and Prevention through USAID to harmonize approaches, such as procurement of viral load instruments.

We also work with our country programs to ensure that the most recent information about new ARVs and the most effective ARV regimens is informing their work with ministries of health. 

GHSC-PSM works to build and maintain strategic partnerships and to support USAID’s leadership among key stakeholders in the global community. Most notable in the HIV/AIDS arena are partnerships with The Global Fund, the World Health Organization, the African Society for Laboratory Medicine, and consortia such as the Antiretroviral Procurement Working Group and initiatives such as the UNITAID-funded Point of Care Early Infant Diagnosis Partner Consortium.

The project’s market dynamics efforts aim to further shape and strengthen the market for ARVs, HIV rapid test kits, viral load laboratory equipment and supplies, and other key commodities. Based on needs identified by market dynamics analysis, GHSC-PSM also advocates for changes in policy and practice.